IL13 and neoplasm: The a-GalCer-loaded whole tumor vaccine primes iNKT in the lung-draining lymph nodes with the release of cytokines, including IL-4, IL-13, and IFN-γ, into the serum and is effective against established intracranial tumors but requires depletion of regulatory T cells (Treg).